HK1197025A1 - Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation 4--3[[4-(3-)-2-]]-n-[5-(4--1h--1- )-3-()] - Google Patents

Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation 4--3[[4-(3-)-2-]]-n-[5-(4--1h--1- )-3-()]

Info

Publication number
HK1197025A1
HK1197025A1 HK14110470A HK14110470A HK1197025A1 HK 1197025 A1 HK1197025 A1 HK 1197025A1 HK 14110470 A HK14110470 A HK 14110470A HK 14110470 A HK14110470 A HK 14110470A HK 1197025 A1 HK1197025 A1 HK 1197025A1
Authority
HK
Hong Kong
Prior art keywords
methyl
imidazol
pyridinyl
pyrimidinyl
trifluoromethyl
Prior art date
Application number
HK14110470A
Other languages
Chinese (zh)
Inventor
Upkar Bhardwaj
Mangesh Sadashiv Bordawekar
Ann Reese Comfort
Ping Li
Shoufeng Li
Alexey Makarov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1197025A1 publication Critical patent/HK1197025A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
HK14110470A 2011-11-14 2014-10-21 Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation 4--3[[4-(3-)-2-]]-n-[5-(4--1h--1- )-3-()] HK1197025A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161559281P 2011-11-14 2011-11-14
PCT/US2012/064610 WO2013074432A1 (en) 2011-11-14 2012-11-12 Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation

Publications (1)

Publication Number Publication Date
HK1197025A1 true HK1197025A1 (en) 2015-01-02

Family

ID=47324402

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14110470A HK1197025A1 (en) 2011-11-14 2014-10-21 Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation 4--3[[4-(3-)-2-]]-n-[5-(4--1h--1- )-3-()]

Country Status (22)

Country Link
EP (1) EP2779995A1 (en)
JP (1) JP6275645B2 (en)
KR (1) KR20140093230A (en)
CN (1) CN103930094A (en)
AR (1) AR088844A1 (en)
BR (1) BR112014011518A2 (en)
CA (1) CA2855503A1 (en)
CL (1) CL2014001247A1 (en)
CO (1) CO6960546A2 (en)
EA (1) EA201490960A1 (en)
GT (1) GT201400094A (en)
HK (1) HK1197025A1 (en)
IL (1) IL232480A0 (en)
IN (1) IN2014DN03416A (en)
MA (1) MA35636B1 (en)
MX (1) MX2014005874A (en)
PE (1) PE20141337A1 (en)
SG (2) SG11201401476TA (en)
TN (1) TN2014000177A1 (en)
TW (1) TWI574690B (en)
WO (1) WO2013074432A1 (en)
ZA (1) ZA201402756B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CZ2017821A3 (en) 2017-12-20 2019-07-03 Zentiva, K.S. Dosing of crystalline nilotinib
JP7378279B2 (en) 2019-11-18 2023-11-13 日本化薬株式会社 Pharmaceutical tablet containing nilotinib as an active ingredient and method for producing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0215676D0 (en) * 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GT200600315A (en) 2005-07-20 2007-03-19 CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA
GT200600316A (en) 2005-07-20 2007-04-02 SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA.
EP1923053A1 (en) * 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
US20100136097A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Systems for modulating inflammation
WO2012164578A1 (en) * 2011-06-02 2012-12-06 Hetero Research Foundation Compositions and methods for preparing immediate release formulations of nilotinib

Also Published As

Publication number Publication date
TW201325594A (en) 2013-07-01
IL232480A0 (en) 2014-06-30
AU2012339829B2 (en) 2016-05-12
MX2014005874A (en) 2014-06-23
TN2014000177A1 (en) 2015-09-30
EP2779995A1 (en) 2014-09-24
AU2012339829A1 (en) 2014-05-29
SG11201401476TA (en) 2014-10-30
CN103930094A (en) 2014-07-16
PE20141337A1 (en) 2014-10-16
WO2013074432A1 (en) 2013-05-23
CL2014001247A1 (en) 2014-10-17
AR088844A1 (en) 2014-07-10
KR20140093230A (en) 2014-07-25
TWI574690B (en) 2017-03-21
CA2855503A1 (en) 2013-05-23
MA35636B1 (en) 2014-11-01
SG10201707768RA (en) 2017-10-30
CO6960546A2 (en) 2014-05-30
JP6275645B2 (en) 2018-02-07
ZA201402756B (en) 2015-04-29
EA201490960A1 (en) 2014-08-29
BR112014011518A2 (en) 2017-05-16
JP2014533283A (en) 2014-12-11
GT201400094A (en) 2017-09-28
NZ623844A (en) 2016-09-30
IN2014DN03416A (en) 2015-06-26

Similar Documents

Publication Publication Date Title
IL229395A0 (en) Modified release of4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide solubilized using organic acids
HK1226069A1 (en) 3,5-diamino-6-chloro-n-(n-(4-(4-(2-(hexyl (2,3,4,5,6-penta-hydroxyhexyl)amino)ethoxy)phenyl)butyl) carbamimidoyl) pyrazine-2-carboxamide
HK1217487A1 (en) N-[4-(2-oxo-1,2-dihydro-pyridin-4-yl)-benzyl]-benzamide derivatives as aldh-2 inhibitors for the treatment of addiction -2 n-[4-(2--12---4- )-]-
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
IL236495A0 (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk)inhibitors
HRP20182059T1 (en) Polymorphs and salts of 6-(1h-indol-4-yl)-4-(5-{ [4-(1-methylethyl)-1-piperazinyl]methyl} -1,3-oxazol-2-yl)-1h-indazole as pi3k inhibitors for use in the treatment of e.g. respiratory disorders
DK2878598T3 (en) Crystalline Form of 4- [5- (PYRIDIN-4-YL) -1H-1,2,4-TRIAZOL-3-YL] PYRIDIN-2-CARBONITRIL
IL237378B (en) 1-(phenyl/pyrid-4-yl)-3-(phenyl-oxazolyl)-5-methyl-1,2,4-triazole derivatives and pharmaceutical compositions comprising them
IL254132B (en) Solid preparation of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n’-methoxyurea or a salt thereof
HK1202237A1 (en) Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)- 1h-pyrazole-4-carboxylic acid 1-(56--1h-[d]-2-)-1h--4-
WO2013150545A8 (en) Process for preparation of benzimidazole derivatives and salts thereof
IL234742A0 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
HK1197025A1 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]- n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide formulation 4--3[[4-(3-)-2-]]-n-[5-(4--1h--1- )-3-()]
SI2608789T1 (en) Therapeutic uses of 1-(2-(2,4-dimethyl-phenylsulfanyl)phenyl)piperazine
PT2943488T (en) Meglumine salt forms of 2-((1 r,4r)-4-(4-(5-(benzoxazol-2-ylamino)pyridin-2-yl)phenyl)cyclohexyl) acetic acid and their use as dgat1 inhibitors
PL394559A1 (en) Capsules containing 4-[(4-methylopiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylopyrimidin-2-yl)amine]phenyl]benzamide and process for the preparation thereof
PL392269A1 (en) Tablet containing 4-[(4-methylopiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylopyrimidin-2-yl)amine]phenyl]benzamide and process for the preparation thereof
PL387516A1 (en) Pharmaceutical composition containing 4-[(4-metyl piperazine-1-yl)methyl]-N-[4-methyl-3-[(4-pyridine-3-yl pyrimidin-2-yl)amino]phenyl]benzamide, method of its manufacturing and the forms of the medicine containing this composition